Date:4/11/2011

file relevant materials, which may include a tender offer statement, and a definitive consent solicitation statement and/or other documents, with the SEC. The definitive consent solicitation statement filed by Valeant with the SEC will include the form of gold consent card to be completed and delivered by each Cephalon stockholder that desires to provide written consent in connection with the consent solicitation.  ALL INVESTORS AND SECURITY HOLDERS OF CEPHALON ARE URGED TO READ ANY SUCH DOCUMENTS FILED WITH THE SEC BY VALEANT CAREFULLY AND IN THEIR ENTIRETY, BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT ANY SUCH TRANSACTION. Investors and security holders will be able to obtain free copies of documents filed with the SEC by Valeant (when they become available) in the same manner as set forth above with respect to the preliminary consent solicitation statement.

(1) Share price calculated off of 29-Mar-2011 closing price, prior to Valeant's public offer.

Contact Information:
Investors:
Laurie W. Little
Valeant Pharmaceuticals International, Inc.
949-461-6002
laurie.little@valeant.com

Media:
Renee E. Soto
Sard Verbinnen & Co.
212-687-8080
rsoto@sardverb.com

Cassandra Bujarski
Sard Verbinnen & Co.
212-687-8080
cbujarski@sardverb.com

(Logo:  http://photos.prnewswire.com/prnh/20101025/LA87217LOGO)

'/>"/>

SOURCE Valeant Pharmaceuticals International, Inc. Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6
Related medicine technology :

1. Valeant Pharmaceuticals Files Preliminary Consent Solicitation Statement With the SEC
2. Promius Pharma and Valeant Form Collaboration to Market Cloderm® Cream in the United States
3. Valeant Pharmaceuticals Proposes to Acquire Cephalon, Inc. for $73 Per Share in Cash
4. GSK and Valeant Receive European Authorisation for Trobalt (retigabine)
5. Valeant Pharmaceuticals Extends Contract with J. Michael Pearson as CEO and Appoints Him as Chairman of the Board
6. Valeant Pharmaceuticals Completes Acquisition of PharmaSwiss S.A.
7. Valeant Announces Pricing of Senior Notes
8. Valeant Launches Senior Notes Offering
9. Valeant Pharmaceuticals to Present at RBC Capital Markets 2011 Healthcare Conference
10. Valeant Pharmaceuticals to Announce 2010 Fourth Quarter and Full Year Results on February 24, 2011
11. Valeant Pharmaceuticals Announces License Of ACZONE® (dapsone) Gel 5% In Canada